Intuitive Surgical new robot a 'major new product platform,' says William Blair William Blair believes Intuitive Surgical's just launched da Vinci Xi robot is a "major new product platform." After attending the Society of American Gastrointestinal and Endoscopic Surgeons meeting, the firm says the clinical reaction to the product is "compelling." It raised its estimate of the total addressable market for Intuitive procedures by 44% and keeps an Outperform rating on the stock.
Intuitive Surgical initiated with an Overweight, $575 target at Barclays Barclays analyst Matthew Taylor started shares of Intuitive Surgical with an Overweight rating and $575 price target. Taylor thinks surgery share will continue to shift to robotic and believes demand for Intuitive's da Vinci among general surgeons is very high. The stock closed yesterday down $4.17 to $492.45.